 |
| Attached files |
| File | Filename |
|---|
| EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | Financial_Report.xls |
| 10-Q - ERGO 10-Q 09/30/12 - Entia Biosciences, Inc. | ergo10q_093012apg.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R8.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R7.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R36.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R42.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R43.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R40.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R25.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R34.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R31.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R29.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R37.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R35.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R17.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R32.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R33.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R39.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R28.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R23.htm |
| EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc. | ex32_1apg.htm |
| EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc. | ex31_1apg.htm |
| EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc. | ex32_2apg.htm |
| EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc. | ex31_2apg.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R26.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R41.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R38.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R30.htm |
| XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc. | R27.htm |
v2.4.0.6
|
NOTE 7 - NOTES PAYABLE
|
9 Months Ended |
|
Sep. 30, 2012
|
| Debt Disclosure [Abstract] |
|
| NOTE 7 - NOTES PAYABLE |
NOTE 7 – NOTES PAYABLE
Notes payable consists of the following:
| |
|
|
September 30, 2012 |
|
December 31, 2011 |
| Notes payable - current |
|
|
|
| 4.85%, unsecured, due monthly |
415 |
|
20,664 |
| 7.85% unsecured, due monthly |
2,812 |
|
2,493 |
| |
|
|
$ 3,227 |
|
$ 23,157 |
| Convertible notes payable, net |
|
|
|
| 5% unsecured due June 2013 (net of discount related to beneficial conversion feature of $0 in 2012 and $5,143 in 2011), convertible into preferred stock at $5.00 per share |
$ 15,000 |
|
$ 9,857 |
| 5%, unsecured due June 2013 (net of discount related to beneficial conversion feature of $35,807 in 2012 and $127,701 in 2011), convertible into common stock at $0.45 per share |
276,693 |
|
184,799 |
| 6% unsecured due June 2013 (net of discount related to beneficial conversion feature of $6,416 in 2012 and $0 in 2011), convertible into preferred stock at $5.00 per share |
6,584 |
|
|
| 5% unsecured due June 2013, convertible into preferred stock at $5.00 per share |
15,000 |
|
15,000 |
| 6% unsecured, convertible into common stock at $2.00 per share, due on demand |
50,000 |
|
50,000 |
| Less: Current Portion |
(363,277) |
|
(194,656) |
| |
|
|
$ - |
|
$ 65,000 |
| |
|
|
|
|
|
| Convertible notes payable related party, net |
|
|
|
| 6% unsecured due December 2013 (net of discount related to beneficial conversion feature of $14,530 in 2012 and $0 in 2011), convertible into common stock at $2.00 per share |
$ 60,470 |
|
$ 50,000 |
Entia had debt in the principal
amount of $392,500 in the form of convertible notes payable of which $377,500 was to mature on June 30, 2012. Entia was successful
in renegotiating all but one of these notes to extend their maturity dates to June 30, 2013. $50,000 of the debt was extended month-to-month,
and as such, all is classified as short-term on the balance sheet. In consideration for extending the maturity date, Entia issued
50,000 warrants valued at $48,533 and modified an existing conversion feature for one of the notes.
For one of the convertible
notes payable modified in the second quarter, we deemed the terms of the note modification to be substantially different due to
the change in the conversion rate and treated the convertible note payable as extinguished and exchanged for a new note. We recorded
a gain of $75,315 on the extinguishment.
|
| X |
- Details
| Name: |
us-gaap_DebtDisclosureAbstract |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:stringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19, 20, 22
-Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
+ Details
| Name: |
us-gaap_DebtDisclosureTextBlock |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
nonnum:textBlockItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by Entia Biosciences, Inc. and has no official or unofficial affiliation with Entia Biosciences, Inc.
Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|
